

New drug submissions— November 2019 APC Decisions



Medicine	Traffic light status	Indication	Other Information
Dapagliflozin	AMBER 2	<u>Type 1</u> diabetes in adults with BMI of at least 27kg/m ² ,	NICE TA597 Prescribing should only be transferred to primary care once a reduction of HbA1c within a 6 month period has been seen
Xonvea® (10mg doxylamine succinate and 10mg pyridoxine hydrochloride)	GREY	Nausea and vomiting in pregnancy	Insufficient evidence to show that this product was superior to products already on the formulary. Not cost effective

News from the APC - updated/new documents on the APC website:

- [Gynecomastia guidelines \(Update\)](#)
- [Solar Keratosis Guideline \(Update\)](#)
- [Medicines and falls chart \(Update\)](#)
- [Opioid guideline \(Interim update\)](#)
- [Low priority list \(Update\)](#)
- [RED/GREY repatriation letter \(New\)](#)
- [Penicillin allergy awareness leaflet \(Update\)](#)



News from the APC

European Medicines Agency drug safety update - [Four-week limit for use of high-strength estradiol creams](#) recommended limiting the use of high-strength creams containing 100 micrograms/gram (0.01%) of estradiol to a single treatment period of up to 4 weeks. This measure is intended to minimise the risk of side effects caused by estradiol absorbed into the bloodstream from creams applied inside the vagina to treat symptoms of vaginal atrophy in women who have been through menopause. High-strength estradiol creams should not be prescribed with other HRT medicines.

Horizon Scanning, Formulary amendments and traffic light changes

Horizon scanning - GREY classification assigned until formal submission

- Diclofenac 3% gel
- Bee Venom
- Wasp Venom
- Volanesorsen sodium - NICE guidance due in 2020

Formulary amendments and traffic light changes:

- Solifenacin 1mg/ml - **GREEN** with restrictions – For use in cases of swallowing difficulty where using oxybutynin patches is not suitable.
- Anthelios XL (SPF 50+) Sunscreen Cream - **GREEN** as a cost effective option.
- Kelhale inhaler - **GREEN**, preferred brand for new patients and when Qvar is not available.

Current work in development

- Melatonin evidence and guideline review
- COPD guideline (Update)
- End of life guidelines (Update)
- ADHD shared care protocols for children and adolescents (Update)
- Overactive bladder guideline (Update)
- Infant feeds - Premature Infants
- Headache in adults guideline
- Testosterone shared care for hypogonadism and delayed puberty in adolescents

Upcoming NICE publications

Title	Type	Anticipated publication date
Acute kidney injury: prevention, detection and management	Guidance	December 2019
Insect bites and stings antimicrobial prescribing	Guidance	December 2019
Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management	Guidance	December 2019
Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome	TA	December 2019
Asthma: diagnosis, monitoring and chronic asthma management	Guidance	February 2020
Impetigo: antimicrobial prescribing	Guidance	February 2020
Patiromer for treating hyperkalaemia	TA	February 2020
Leg ulcer infection: antimicrobial prescribing	Guidance	February 2020

The work of the NAPC is supported and managed by the interface team below. They can be contacted via MACCG.NottsAPC@nhs.net
Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG
Shadia Jenner, Primary Care Pharmacist, Mansfield&Ashfield CCG (covering Irina Varlan's maternity leave)
Karen Robinson, APC and Formulary Support Technician, Nottinghamshire Health Community
Nick Sherwood, Specialist Mental Health Efficiencies Pharmacist, Notts Healthcare Trust
Deepa Tailor, Primary Care Pharmacist, Nottingham City CCG (covering Lynne Kennell's maternity leave)
Jill Theobald, Specialist Interface Efficiencies Pharmacist, Greater Nottingham CCP